Sarepta share price drops again after third gene therapy death
Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment. A …
Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment. A …
Velocity Clinical Research has partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials, marking an advancement …
UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI). The company was …
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet …
The UK Medical and Healthcare products Regulatory Agency (MHRA) has granted approval for Cybin to initiate the randomised EMBRACE study …
According to the US Centers for Disease Control and Prevention (CDC), a third of US teenagers are prediabetic, meaning that …
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and …
While more companies are using real-world data (RWD) and real-world evidence (RWE) in research, there are still barriers that continue …
Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. Mod3 Pharma was previously …
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A …
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), …
This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia …
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met …